Promentis Pharmaceuticals Inc., Marquette’s first-ever pharmaceutical start-up company, received a three-year, $1.8 million Small Business Innovation Research award from the National Institutes of Health to develop more effective drugs to treat schizophrenia. The award will support efforts to take Promentis’ most promising compounds to the beginning of clinical trials. The company also received a $299,000 grant from the Michael J. Fox Foundation to conduct further research into compounds that show promise for treating Parkinson’s disease.
Promentis Pharmaceuticals Inc., founded by Drs. David Baker and John Mantsch, both professors in the Department of Biomedical Sciences, is focused on creating new therapeutic targets for central nervous system disorders. Dr. Baker currently serves as a director for Promentis and chairs its Scientific Advisory Board.